Pharmacy World and Science

, Volume 17, Issue 3, pp 81–86 | Cite as

Analysis of pharmacotherapy of hypertension in out-patients

  • J. Vlček
  • M. Tesařová
  • Z. Fendrich


In the present pilot study an attempt was made to evaluate the usefulness of results obtained about the treatment of patients suffering from high blood pressure for a pharmacoepidemiological study of the therapeutic value of antihypertensive agents. Data from 90 hypertensive patients were used in the present retrospective-prospective study. These patients all attended an out-patient clinic located in one of the East-Bohemian districts that are participating in the MONICA programme. Instead of the analysis of the population data, regular blood pressure measurements, plasma glucose levels, and total cholesterol concentrations were measured and analysed. The consumption of various antihypertensive drugs in this study was similar to that found in larger studies performed in other health districts of the Czech Republic. Diuretics were the drugs most frequently prescribed for hypertensive patients. General practitioners rarely prescribed calcium channel blockers and angiotensin-converting enzyme inhibitors in 1990 and 1991. The metabolic effects of antihypertensive drugs, mostly diuretics, were not significantly evident. The most frequent occurrence of non-compensated blood pressure was recorded for the treatments with Trimecryton® and methyldopa. However, the validity of these findings should be tested in a larger group of hypertensic patients.


Angiotensin-converting enzyme inhibitors Blood pressure Calcium channel blockers Cholesterol Diuretics Drug utilization Glucose Hypertension Out-patients Pharmacoepidemiology 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Westfall DP. Pharmacological treatment of hypertension. In: Craig CR, Stitzel RE, editors. Modern pharmacology. 3rd edn. Boston: Little, Brown and Company, 1990:271–98.Google Scholar
  2. 2.
    Turner RR. Role of quality of life in hypertension therapy: Implication for patient compliance. Cardiology 1992;80 Suppl 1:11–22.Google Scholar
  3. 3.
    Ames RP. The effects of antihypertensive drugs on serum lipids and lipoproteins I. Diuretics. Drugs 1986;32:260–78.Google Scholar
  4. 4.
    Widimský J, Dzurik R, Dzuriková V. Farmakoterapie hypertenze [Pharmacotherapy of hypertension]. In: Widimský J, editor. Kardiovaskulární farmakoterapie [Cardiovascular pharmacotherapy]. Prague: Avicenum, 1987:159–208.Google Scholar
  5. 5.
    Maënpää H, Männinen V, Heinonen OP. Comparison of the digoxin maker with capsule counting and compliance questionnaire methods for measuring compliance to medication in a clinical trial. Eur Heart J 1987;8 Suppl 1:39–43.Google Scholar
  6. 6.
    Morgenstern H, Winn DM. A method for determining of sampling ratio in epidemiologic studies. Stat Med 1983;2:387–96.Google Scholar
  7. 7.
    Neal WW. Reducing cost and improving compliance. Am J Cardiol 1989;63:17B-20B.Google Scholar
  8. 8.
    Dollery CT. Clinical pharmacology of calcium antagonists. Am J Hypertens 1991;4:84–7.Google Scholar
  9. 9.
    Probstfield JL, Applegate WB, Borhani NO, Curb JD, Cutler JA, Davis BR, et al. The systolic hypertension in the elderly program (SHEP). SHEP cooperative research group. Clin Exp Hypertens 1989;11:973–89.Google Scholar
  10. 10.
    Ames P. Coronary heart disease and the treatment of hypertension: Impact of diuretics on serum lipids and glucose. J Cardiovasc Pharmacol 1984;6:S466–73.Google Scholar
  11. 11.
    Cruickshank JM. The case for beta-blockers as first-line antihypertensive therapy. J Hypertens 1992;10 Suppl 3:521–7.Google Scholar
  12. 12.
    Skodová Z, Píža Z, Emrová R, Vorlíček J, Vojtíšek P, Berka L, et al. Cardiovascular risk factors in the Czech population. Cor Vasa 1991;3:114–22.Google Scholar
  13. 13.
    Bothig S. WHO MONICA Project: Objectives and design. Int J Epidemiol 1989;18 Suppl 1:S29–37.Google Scholar
  14. 14.
    Ulrich J, Hajnová J, Alferi D. Po deseti letech opět o hypertensi v chemických závodech v Litvínově. [After ten years again about hypertension in chemical industry in Litvínov]. Prakt Lekar 1990;70:692–5.Google Scholar
  15. 15.
    The fifth report of the joint national committee on detection, evaluation, and treatment of high blood pressure. Arch Intern Med 1993;153:145–208.Google Scholar
  16. 16.
    Žáková A. Využití isometrické zátěže při hypertenzi [Utilisation of isometric load at hypertension]. Prakt Lekar 1991; 71:469–70.Google Scholar
  17. 17.
    Rogers HJ, Spector RG, Trounce JR. A textbook of clinical pharmacology, 1st edn. London: Hodder and Stoughton, 1981:425–7.Google Scholar
  18. 18.
    Curb JD, Borhami NO, Blaszkowski TP, Zimbaldi N, Williams W, Fotiu S, et al. Long-term surveillance for adverse effects of antihypertensive drugs. JAMA 1985;253:3263–8.Google Scholar
  19. 19.
    Murphy MB, Kohner E, Lewis PJ, Schuner B, Dollery CI. Glucose intolerance in hypertensive patients treated with diuretics. A fourteen-year follow-up. Lancet 1982;2:1293–5.Google Scholar
  20. 20.
    Medical Research Council trial of treatment of hypertension in older adults: principal results. BMJ 1992;304:405–12.Google Scholar
  21. 21.
    Sclar DA, Chin A, Skaer TL, Okamoto MP, Nakahiro RK, Gill MA. Effect of first education on the utilisation of antihypertensive therapy: A prospective trial among WHO enrolees. Prim Cardiol 1992;Suppl 1:24–9.Google Scholar
  22. 22.
    Collins R, Peto R, McMahon S, Hebert P, Fiebach NH, Eberlein KA. Blood pressure, stroke, and coronary heart disease. Part 2. Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 1990;335:827–38.Google Scholar
  23. 23.
    Tortorice KL, Carter BL. Stroke prophylaxis: hypertension management and antithrombotic therapy. Ann Pharmacother 1993;27:471–9.Google Scholar

Copyright information

© Royal Dutch Association for Advancement of Pharmacy 1995

Authors and Affiliations

  • J. Vlček
    • 1
  • M. Tesařová
    • 1
  • Z. Fendrich
    • 2
  1. 1.Department of Social and Clinical Pharmacy Faculty of PharmacyCharles UniversityHradec KrálovéCzech Republic
  2. 2.Department of Pharmacology and Toxicology, Faculty of PharmacyCharles UniversityHradec KrálovéCzech Republic

Personalised recommendations